KJC Statistics is proud to be part of the Kidney Health Initiative. The aim of the KHI is to “advance…
Novel, adaptive designs are seen by many drug developers as highly attractive as they seemingly offer more for less: more…
FDA reviews the learning from 22 case studies. Despite what are often reported as promising phase II data, the subsequent…
As if justifying one wasn’t tough enough…now Sponsor have two non-inferiority margins to deal with?! Dealing with FDA’s new guidance…
KJC statistics is pleased to announce a working collaboration with Ms Claire Watkins, MSc, of ClaroStat Consulting. Claire has over…
